Draft:Marc Buyse
Submission declined on 20 August 2026 by Thilsebatti (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
This draft's references do not show that the subject meets Wikipedia's criteria for inclusion for academics. The draft requires either:
Declined by Qcne 18 days ago.
or multiple published secondary sources that:
| |
Marc Buyse is a Belgian biostatistician, entrepreneur, and academic. He is the founder of One2Treat, the International Drug Development Institute (IDDI), and CluePoints, and is Associate Professor of Biostatistics at Hasselt University. He previously worked at the European Organisation for Research and Treatment of Cancer (EORTC) in Brussels and the Dana–Farber Cancer Institute in Boston.[1]
Buyse's research has focused on clinical trial methodology, meta-analysis, surrogate endpoint validation, and statistical methods in oncology. He is particularly known for his work on Generalized Pairwise Comparisons (GPC), a statistical framework for comparing treatments across multiple prioritized outcomes. In 2010, Buyse formally introduced GPC as a general method for comparing groups using multiple outcomes, including binary, continuous and time-to-event outcomes.[2]
GPC has subsequently been developed and applied across clinical research. A 2023 review in the Journal of the American College of Cardiology described GPC as a way of overcoming limitations of conventional time-to-first-event composite endpoints by allowing multiple outcomes, including the severity of events, recurrent events and clinically relevant non-survival outcomes, to be incorporated into the assessment of treatment benefit.[3] The method has been applied in cardiovascular research, oncology and benefit-risk assessment, including analyses of randomized clinical trials in which efficacy and toxicity are considered jointly.[4][5]
The GPC framework provides the basis for measures of treatment effect including Net Treatment Benefit (NTB), which summarizes the balance of favorable and unfavorable outcomes across prioritized endpoints.[6] More recent applications have used GPC and NTB to assess treatment benefit according to different priorities, including patient-specific benefit-risk assessment in the CODA trial comparing antibiotics with appendectomy for acute appendicitis.[7][3]
Buyse's 2010 paper introducing GPC has received more than 200 citations in both Scopus and Web of Science, according to the Hasselt University research repository.[8]
Buyse has served as President of the International Society for Clinical Biostatistics and President of the Quetelet Society, and is a Fellow of the Society for Clinical Trials.
Selected works
[edit]- Buyse, Marc. "Generalized pairwise comparisons of prioritized outcomes in the two-sample problem." Statistics in Medicine, 2010.
- Generalized Pairwise Comparisons and Net Treatment Benefit. Chapman & Hall/CRC, 2021.
- Verbeeck, Johan; De Backer, Mickaël; Verwerft, Jan; et al. "Generalized Pairwise Comparisons to Assess Treatment Effects: JACC Review Topic of the Week." Journal of the American College of Cardiology, 2023.
References
[edit]- ↑ "Marc Buyse". Hasselt University. Retrieved 19 August 2026.
- ↑ Buyse, Marc (2010). "Generalized pairwise comparisons of prioritized outcomes in the two-sample problem". Statistics in Medicine. 29 (30): 3245–3257. doi:10.1002/sim.3923. PMID 21170918.
- 1 2 Verbeeck, Johan; De Backer, Mickaël; Verwerft, Jan; Salvaggio, Samuel; Valgimigli, Marco; Vranckx, Pascal; Buyse, Marc; Brunner, Edgar (2023). "Generalized Pairwise Comparisons to Assess Treatment Effects: JACC Review Topic of the Week". Journal of the American College of Cardiology. 82 (13): 1360–1372. doi:10.1016/j.jacc.2023.06.047. hdl:1942/42083. PMID 37730293.
- ↑ Buyse, Marc; Ciani, Orianna (2021). "The Net Benefit of a treatment should take the correlation between benefits and harms into account". Journal of Clinical Epidemiology. 137: 222–228. doi:10.1016/j.jclinepi.2021.03.018. PMID 33774140.
- ↑ Chamseddine, Ali N.; Oba, Koji; Buyse, Marc; et al. (2021). "Impact of follow-up on generalized pairwise comparisons for estimating the irinotecan benefit in advanced/metastatic gastric cancer". Contemporary Clinical Trials. 105 106400. doi:10.1016/j.cct.2021.106400. PMID 33866004.
- ↑ Buyse, Marc (2021). Generalized Pairwise Comparisons and Net Treatment Benefit. Chapman & Hall/CRC.
- ↑ De Backer, Mickaël; Sengar, Manju; Mathews, Vikram; Salvaggio, Samuel; Deltuvaite-Thomas, Vaiva; Chiem, Jean-Christophe; Saad, Everardo D.; Buyse, Marc (2024). "Design of a clinical trial using generalized pairwise comparisons to test a less intensive treatment regimen". Clinical Trials. 21 (2): 180–188. doi:10.1177/17407745231206465. PMC 11195000. PMID 37877379.
- ↑ Buyse, Marc (2010). "Generalized pairwise comparisons of prioritized outcomes in the two-sample problem". Statistics in Medicine. 29 (30). Hasselt University: 3245–3257. doi:10.1002/sim.3923. PMID 21170918. Retrieved 19 August 2026.
- provide significant coverage: discuss the person in detail, not brief mentions or interviews lacking independent analysis;
- are reliable: from reputable outlets with editorial oversight;
- are independent: not connected to the person, such as interviews, press releases, the subject's own website, or sponsored content.
Please add references that meet all three of these criteria. If none exist, the subject is not yet suitable for Wikipedia.